Jenburkt Pharmaceuticals (524731) Q2 24/25 earnings summary

Executive summary

• Unaudited financial results for the quarter and half year ended 30th September 2024 were approved by the Board on 5th November 2024.

• The company operates exclusively in the pharmaceuticals segment.

Financial highlights

• Revenue from operations for Q2 FY25 was ₹4,121.59 lakhs, up from ₹3,828.94 lakhs in Q2 FY24.

• Net profit after tax for Q2 FY25 stood at ₹1,060.57 lakhs, compared to ₹791.53 lakhs in Q2 FY24.

• Earnings per share (EPS) for Q2 FY25 was ₹21.75, up from ₹16.59 in Q2 FY24.

• Total comprehensive income for H1 FY25 was ₹1,957.25 lakhs, compared to ₹1,437.33 lakhs in H1 FY24.

Outlook and guidance

• The company continues to focus on its core pharmaceuticals business, with no segment diversification reported.